Angiex’s Antibody-Drug Conjugate AGX101 Enters Phase I Clinical Trials
Angiex has reached a key milestone with the initiation of Phase I clinical trials for AGX101, its TM4SF1-directed antibody-drug conjugate (ADC) designed to target solid tumors. This novel ADC works by disrupting the blood vessels that feed tumors, offering a targeted approach to treating some of the most aggressive forms of cancer. AGX101’s entry into clinical trials represents a major step forward in the development of precision cancer therapies.
Drug Discovery World reported on this important development, spotlighting AGX101’s potential to transform the treatment landscape for solid tumors. Known for covering the latest breakthroughs in drug discovery and development, Drug Discovery World provides valuable insights into the significance of AGX101’s innovative mechanism of action. The article explores how this therapy could offer new hope for patients facing difficult-to-treat cancers.